DCAL vs GLENMARK: Stock Comparison
GLENMARK PHARMACEUTICALS is the larger company by market capitalisation. DISHMAN CARBO AMCIS shows faster revenue growth and a higher ROCE, while GLENMARK PHARMACEUTICALS shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
DCAL leads 4; GLENMARK leads 7 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | DCAL | GLENMARK |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | DCAL | GLENMARK |
|---|---|---|
| Live Price | ₹140.02 | ₹2,198.5 |
| Day Change | -1.46% | 0.2% |
| Volume | 1.95 L | 5.77 L |
| 52-Week High | ₹303 | ₹2,537.6 |
| 52-Week Low | ₹128.5 | ₹1,792.6 |
| Distance from 52W High | -53.79% | -13.36% |
Valuation
| Metric | DCAL | GLENMARK |
|---|---|---|
| Market Cap | ₹2,195 Cr | ₹61,612 Cr |
| P/E Ratio | 135.92x | 41.17x |
| P/B Ratio | 0.33x | 5.86x |
| EPS | ₹-3.69 | ₹17.11 |
| Book Value | ₹425.87 | ₹372.49 |
| Dividend Yield | 0% | 0.11% |
Growth
| Metric | DCAL | GLENMARK |
|---|---|---|
| Revenue Growth (TTM YoY) | 18.9% | 14.3% |
| EPS Growth (TTM YoY) | -49.5% | 6,575% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | DCAL | GLENMARK |
|---|---|---|
| ROE | -0.99% | -0.83% |
| ROCE | 0.61% | -0.79% |
| Net Margin | 2.51% | 8.15% |
| Operating Margin | 11.78% | -2.22% |
| Debt to Equity | 0.16x | 0x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | DCAL | GLENMARK |
|---|---|---|
| Promoter Holding | 59.32% | 46.65% |
| FII Holding | 6.86%▼ 0.59 pp | 20.89%▲ 0.55 pp |
| DII Holding | 2.07%▲ 0.44 pp | 18.6%▼ 0.69 pp |
| Public Holding | 31.75%▲ 0.15 pp | 13.81%▲ 0.13 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: DISHMAN CARBO AMCIS and GLENMARK PHARMACEUTICALS.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.